Polycythemia vera and its molecular basis: An update

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 3, 2006, Pages 387-397

  Chen, George ^a   Prchal, Josef T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

clonality; erythroid progenitors; JAK 2; polycythemia vera

Indexed keywords

ANDROGEN RECEPTOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMATINIB; JANUS KINASE 2; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

CHROMOSOME INACTIVATION; CLINICAL TRIAL; CLONAL VARIATION; COLONY FORMATION; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; DRUG EFFICACY; ENZYME INHIBITION; ERYTHROID CELL; GENE MUTATION; GENETIC CORRELATION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RELIABILITY; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; JANUS KINASE 2; MUTATION; POLYCYTHEMIA VERA; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 33745079590     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.07.003     Document Type: Review

References (44)

1. Beutler E. Polycythemia. In: Beutler E., Lichtman M., Coller B., et al. (Eds). Williams Hematology. 6th edn (2001), McGraw-Hill, New York 689-701
2. James C., Ugo V., Le Couedic J.-P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434 (2005) 1144-1148
3. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
4. Levine R., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
5. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
6. Zhao R, Xing S, Li Z, et al. Identification of an Acquired JAK2 Mutation in Polycythemia vera. J Biol Chem 2005; 280: 22788-22792.
7. Carrel L., and Willard H.F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434 7031 (2005) 400-404
8. Beutler E., Yeh M., and Fairbanks V.F. The normal human female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD deficiency as a marker. Proc Natl Acad Sci U S A 48 (1962) 9-16
9. Vogelstein B., Fearon E.R., Hamilton S.R., and Feinberg A.P. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science 227 (1985) 642
10. Fearon E.R., Winkelstein J.A., Civin C.I., et al. Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med 316 (1987) 427-431
11. Abrahamson G., Fraser N.J., Boyd Y., and Craig I. X-chromosome inactivation patterns using HGPRT and PGK polymorphisms in haematologically normal and post chemotherapy females. Br J Haematol 74 (1990) 371-372
12. Gilliland D.G., Blanchard K.L., Levy J., et al. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 88 (1991) 6848-6852
13. Curnutte J.T., Hopkins P.J., Kuhl W., and Beutler E. Studying X-inactivation. Lancet 339 (1992) 749
14. Prchal J.T., Guan Y.L., Prchal J.F., and Barany F. Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis. Blood 81 (1993) 269-271
15. Liu E., Jelinek J., Pastore Y.D., et al. Discrimination of polycythemias and thrombocytosis by novel, simple, accurate clonality assays and BFU-E response to erythropoietin. Blood 101 (2003) 3294-3301
16. Prchal J.T. Polycythemia vera and other primary polycythemias. Curr Opin Hematol 12 (2005) 112-116
17. Kralovics R., Guan Y., and Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematology 30 (2002) 229-236
18. Prchal J.F., and Axelrad A.A. Letter: bone-marrow responses in polycythemia vera. N Engl J Med 290 (1974) 1382
19. Fisher M.J., Prchal J.F., Prchal J.T., and D'Andrea A.D. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 84 (1994) 1982-1991
20. Ugo V., et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematology 32 (2004) 179-187
21. Saharinen P., Takaluoma K., and Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 20 (2000) 3387-3395
22. Luo H., et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 17 (1997) 1562-1571
23. Hunter T. Signaling - 2000 and beyond. Cell 100 (2000) 113-127
24. Blume-Jensen P., and Hunter T. Oncogenic kinase signaling. Nature 411 (2001) 355-365
25. Dai C.H., Krantz S.B., and Sawyer S.T. Polycythemia vera V, Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. Blood 89 (1997) 3574-3581
26. Xu M.J., Sui X., Zhao R., et al. PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood 102 (2003) 4354-4360
27. Neel B.G., Gu H., and Pao L. The "Shp"ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28 (2003) 284-293
28. Tsui H.W., Siminovitch K.A., Souza L., and Tsui F.W.L. Motheaten and viable motheaten mice have mutations in the hematopoietic cell phosphatase gene. Nat Genet 4 (1993) 124-129
29. Shultz L.D., Schweitzer P.A., Rajan T.V., et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein tyrosine phosphatase (HCPH) gene. Cell 73 (1993) 1445-1454
30. Prchal J.F., and Prchal J.T. Molecular basis for polycythemia. Curr Opin Hematol 6 (1999) 100-109
31. Klingmuller U., Lorenz U., Cantley L.C., et al. Specific recruitment if SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80 (1995) 729-738
32. Asimakopoulos F.A., Hinshelwood S., Gilbert J.G., et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene 14 (1997) 1215-1222
33. Anderson P., LeBlanc K., Eriksson B.-A., and Samuelson J. No evidence for an altered mRNA expression or protein level of hematopoietic cell phosphatase in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythemia vera. Eur J Haematol 59 (1997) 310-317
34. Wickrema A., Chen F., Namin F., et al. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol 27 (1999) 1124-1132
35. Feng G.S. SHP-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res 253 (1999) 47-54
36. Tartaglia M., Niemeyer C.M., Fragale A., et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes, and acute myeloid leukemia. Nat Genet 34 (2003) 148-150
37. Loh M.L., Vattikuti S., Schubbert S., et al. Mutations in PTPN11 implicate the SHP-2 phosphatse in leukemogenesis. Blood 103 (2004) 2325-2331
38. Tartaglia M., Martinelli S., Cazzaniga G., et al. Genetic evidence for lineage and differentiation stage related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104 (2004) 307-313
39. Bentires-Alj M., Paez J.G., David F.S., et al. Activating mutations of the Noonan syndrome associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64 (2004) 8816-8820
40. Marine J.C., McKay C., Wang D., et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98 (1999) 617-627
41. Sasaki A., Yasukawa H., Souda T., et al. CIS3/SOCS-3 suppresses erythropoietin (Epo) signaling by binding the EPO receptor and JAK2. J Biol Chem 275 (2000) 29338-29347
42. Krebs D., and Hilton D.J. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 113 (2000) 2813-2819
43. Steensma DP, Dewald GW, Lasho T, et al. Brief report: the JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1207-1212.
44. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370-3373.